{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:12:01Z","timestamp":1793772721971,"version":"4.6.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000334","name":"International Spinal Research Trust","doi-asserted-by":"publisher","award":["NRB2015"],"award-info":[{"award-number":["NRB2015"]}],"id":[{"id":"10.13039\/501100000334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The acute phase response (APR) to CNS insults contributes to the overall magnitude and nature of the systemic inflammatory response. Aspects of this response are thought to drive secondary inflammatory pathology at the lesion site, and suppression of the APR can therefore afford some neuroprotection. In this study, we examined the APR in a mouse model of traumatic spinal cord injury (SCI), along with its relationship to\u00a0neutrophil recruitment during the immediate aftermath of the insult. We specifically investigated the effect of IL-1 receptor antagonist (IL-1RA) administration on the APR and leukocyte recruitment to the injured\u00a0spinal cord.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Adult female C57BL\/6 mice underwent either a 70kD contusive SCI, or sham surgery, and tissue was collected at 2, 6, 12, and 24 hours post-operation. For IL-1RA experiments, SCI mice received two intraperitoneal injections of human IL-1RA (100mg\/kg), or saline as control, immediately following, and 5 hours after impact, and animals were sacrificed 6 hours later. Blood, spleen, liver and spinal cord were collected to study markers of central and peripheral inflammation by flow cytometry, immunohistochemistry and qPCR. Results were analysed by two-way ANOVA or student\u2019s t-test, as appropriate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>SCI induced a robust APR, hallmarked by elevated hepatic expression of pro-inflammatory marker genes and a significantly increased neutrophil presence in the blood, liver and spleen of these animals, as early as 2 hours after injury. This peripheral response preceded significant neutrophil infiltration of the spinal cord, which peaked 24 hours post-SCI. Although expression of IL-1RA was also induced in the liver following SCI, its response was delayed compared to IL-1\u03b2. Exogenous administration of IL-1RA during this putative therapeutic window was able to suppress the hepatic APR, as evidenced by a reduction in CXCL1 and SAA-2 expression as well as a significant decrease in neutrophil infiltration in\u00a0both the liver and the injured spinal cord itself.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our data indicate that peripheral administration of IL-1RA can attenuate the APR which in turn reduces\u00a0immune cell infiltration at\u00a0the spinal cord lesion\u00a0site. We propose IL-1RA treatment as a viable therapeutic strategy to minimise the harmful effects of SCI-induced inflammation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12974-020-02050-6","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T15:08:48Z","timestamp":1609945728000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Acute IL-1RA treatment suppresses the peripheral and central inflammatory response to spinal cord injury"],"prefix":"10.1186","volume":"18","author":[{"given":"Abi G.","family":"Yates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Jogia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen R.","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Couch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J.","family":"Ruitenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1380-6655","authenticated-orcid":false,"given":"Daniel C.","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"2050_CR1","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.expneurol.2008.10.022","volume":"215","author":"F Bao","year":"2009","unstructured":"Bao F, Bailey CS, Gurr KR, Bailey SI, Rosas-Arellano MP, Dekaban GA, et al. Increased oxidative activity in human blood neutrophils and monocytes after spinal cord injury. Exp Neurol. 2009;215:308\u201316.","journal-title":"Exp Neurol"},{"key":"2050_CR2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3171\/2014.3.SPINE13784","volume":"21","author":"AK Kesani","year":"2014","unstructured":"Kesani AK, Urquhart JC, Bedard N, Leelapattana P, Siddiqi F, Gurr KR, et al. Systemic inflammatory response syndrome in patients with spinal cord injury: does its presence at admission affect patient outcomes? Clinical article. J Neurosurg Spine. 2014;21:296\u2013302.","journal-title":"J Neurosurg Spine"},{"key":"2050_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/NEN.0b013e3181654957","volume":"67","author":"SJ Campbell","year":"2008","unstructured":"Campbell SJ, Anthony DC, Oakley F, Carlsen H, Elsharkawy AM, Blomhoff R, et al. Hepatic nuclear factor kappa B regulates neutrophil recruitment to the injured brain. J Neuropathol Exp Neurol. 2008;67:223\u201330.","journal-title":"J Neuropathol Exp Neurol"},{"key":"2050_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.nbd.2007.04.013","volume":"27","author":"SJ Campbell","year":"2007","unstructured":"Campbell SJ, Deacon RM, Jiang Y, Ferrari C, Pitossi FJ, Anthony DC. Overexpression of IL-1beta by adenoviral-mediated gene transfer in the rat brain causes a prolonged hepatic chemokine response, axonal injury and the suppression of spontaneous behaviour. Neurobiol Dis. 2007;27:151\u201363.","journal-title":"Neurobiol Dis"},{"key":"2050_CR5","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/S0002-9440(10)62365-6","volume":"166","author":"SJ Campbell","year":"2005","unstructured":"Campbell SJ, Perry VH, Pitossi FJ, Butchart AG, Chertoff M, Waters S, et al. Central nervous system injury triggers hepatic CC and CXC chemokine expression that is associated with leukocyte mobilization and recruitment to both the central nervous system and the liver. Am J Pathol. 2005;166:1487\u201397.","journal-title":"Am J Pathol"},{"key":"2050_CR6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1046\/j.1471-4159.2002.01166.x","volume":"83","author":"SJ Campbell","year":"2002","unstructured":"Campbell SJ, Wilcockson DC, Butchart AG, Perry VH, Anthony DC. Altered chemokine expression in the spinal cord and brain contributes to differential interleukin-1beta-induced neutrophil recruitment. J Neurochem. 2002;83:432\u201341.","journal-title":"J Neurochem"},{"key":"2050_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/00004647-200203000-00009","volume":"22","author":"DC Wilcockson","year":"2002","unstructured":"Wilcockson DC, Campbell SJ, Anthony DC, Perry VH. The systemic and local acute phase response following acute brain injury. J Cereb Blood Flow Metab. 2002;22:318\u201326.","journal-title":"J Cereb Blood Flow Metab"},{"key":"2050_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0006-8993(02)03473-X","volume":"958","author":"D Blond","year":"2002","unstructured":"Blond D, Campbell SJ, Butchart AG, Perry VH, Anthony DC. Differential induction of interleukin-1beta and tumour necrosis factor-alpha may account for specific patterns of leukocyte recruitment in the brain. Brain Res. 2002;958:89\u201399.","journal-title":"Brain Res"},{"key":"2050_CR9","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1096\/fj.02-0757fje","volume":"17","author":"SJ Campbell","year":"2003","unstructured":"Campbell SJ, Hughes PM, Iredale JP, Wilcockson DC, Waters S, Docagne F, et al. CINC-1 is an acute-phase protein induced by focal brain injury causing leukocyte mobilization and liver injury. FASEB J. 2003;17:1168\u201370.","journal-title":"FASEB J"},{"key":"2050_CR10","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1111\/j.1471-4159.2007.04928.x","volume":"103","author":"SJ Campbell","year":"2007","unstructured":"Campbell SJ, Jiang Y, Davis AE, Farrands R, Holbrook J, Leppert D, et al. Immunomodulatory effects of etanercept in a model of brain injury act through attenuation of the acute-phase response. J Neurochem. 2007;103:2245\u201355.","journal-title":"J Neurochem"},{"key":"2050_CR11","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1093\/brain\/awl296","volume":"129","author":"JC Fleming","year":"2006","unstructured":"Fleming JC, Norenberg MD, Ramsay DA, Dekaban GA, Marcillo AE, Saenz AD, et al. The cellular inflammatory response in human spinal cords after injury. Brain. 2006;129:3249\u201369.","journal-title":"Brain"},{"key":"2050_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fncel.2016.00098","volume":"10","author":"MA Anwar","year":"2016","unstructured":"Anwar MA, Al Shehabi TS, Eid AH. Inflammogenesis of secondary spinal cord injury. Front Cell Neurosci. 2016;10:98.","journal-title":"Front Cell Neurosci"},{"key":"2050_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12974-014-0150-2","volume":"11","author":"V Neirinckx","year":"2014","unstructured":"Neirinckx V, Coste C, Franzen R, Gothot A, Rogister B, Wislet S. Neutrophil contribution to spinal cord injury and repair. J Neuroinflammation. 2014;11:150.","journal-title":"J Neuroinflammation"},{"key":"2050_CR14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.expneurol.2007.06.009","volume":"209","author":"DJ Donnelly","year":"2008","unstructured":"Donnelly DJ, Popovich PG. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp Neurol. 2008;209:378\u201388.","journal-title":"Exp Neurol"},{"key":"2050_CR15","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jocn.2004.06.011","volume":"12","author":"L Yang","year":"2005","unstructured":"Yang L, Jones NR, Blumbergs PC, Van Den Heuvel C, Moore EJ, Manavis J, et al. Severity-dependent expression of pro-inflammatory cytokines in traumatic spinal cord injury in the rat. J Clin Neurosci. 2005;12:276\u201384.","journal-title":"J Clin Neurosci"},{"key":"2050_CR16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.bbi.2019.06.026","volume":"81","author":"L Zhu","year":"2019","unstructured":"Zhu L, Liu X, Nemeth DP, DiSabato DJ, Witcher KG, McKim DB, et al. Interleukin-1 causes CNS inflammatory cytokine expression via endothelia-microglia bi-cellular signaling. Brain Behav Immun. 2019;81:292\u2013304.","journal-title":"Brain Behav Immun"},{"key":"2050_CR17","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9781139030564","volume-title":"Traumatic brain and spinal cord injury : challenges and developments","author":"C Morganti-Kossmann","year":"2012","unstructured":"Morganti-Kossmann C, Raghupathi R, Maas AIR. Traumatic brain and spinal cord injury : challenges and developments. Cambridge: Cambridge University Press; 2012."},{"key":"2050_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/nri1664","volume":"5","author":"SM Allan","year":"2005","unstructured":"Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol. 2005;5:629\u201340.","journal-title":"Nat Rev Immunol"},{"key":"2050_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1046\/j.1471-4159.2000.740457.x","volume":"74","author":"L Vitkovic","year":"2000","unstructured":"Vitkovic L, Bockaert J, Jacque C. \"inflammatory\" cytokines: neuromodulators in normal brain? J Neurochem. 2000;74:457\u201371.","journal-title":"J Neurochem"},{"key":"2050_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1742-2094-9-65","volume":"9","author":"A Sato","year":"2012","unstructured":"Sato A, Ohtaki H, Tsumuraya T, Song D, Ohara K, Asano M, et al. Interleukin-1 participates in the classical and alternative activation of microglia\/macrophages after spinal cord injury. J Neuroinflammation. 2012;9:65.","journal-title":"J Neuroinflammation"},{"key":"2050_CR21","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1523\/JNEUROSCI.0157-08.2008","volume":"28","author":"JP de Rivero Vaccari","year":"2008","unstructured":"de Rivero Vaccari JP, Lotocki G, Marcillo AE, Dietrich WD, Keane RW. A molecular platform in neurons regulates inflammation after spinal cord injury. J Neurosci. 2008;28:3404\u201314.","journal-title":"J Neurosci"},{"key":"2050_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/cne.21149","volume":"500","author":"I Pineau","year":"2007","unstructured":"Pineau I, Lacroix S. Proinflammatory cytokine synthesis in the injured mouse spinal cord: multiphasic expression pattern and identification of the cell types involved. J Comp Neurol. 2007;500:267\u201385.","journal-title":"J Comp Neurol"},{"key":"2050_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S0006-8993(97)00254-0","volume":"759","author":"CX Wang","year":"1997","unstructured":"Wang CX, Olschowka JA, Wrathall JR. Increase of interleukin-1beta mRNA and protein in the spinal cord following experimental traumatic injury in the rat. Brain Res. 1997;759:190\u20136.","journal-title":"Brain Res"},{"key":"2050_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.bbi.2004.06.001","volume":"19","author":"S Ching","year":"2005","unstructured":"Ching S, He L, Lai W, Quan N. IL-1 type I receptor plays a key role in mediating the recruitment of leukocytes into the central nervous system. Brain Behav Immun. 2005;19:127\u201337.","journal-title":"Brain Behav Immun"},{"key":"2050_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/00005072-199903000-00004","volume":"58","author":"L Schnell","year":"1999","unstructured":"Schnell L, Fearn S, Schwab ME, Perry VH, Anthony DC. Cytokine-induced acute inflammation in the brain and spinal cord. J Neuropathol Exp Neurol. 1999;58:245\u201354.","journal-title":"J Neuropathol Exp Neurol"},{"key":"2050_CR26","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.bbi.2009.11.007","volume":"24","author":"I Pineau","year":"2010","unstructured":"Pineau I, Sun L, Bastien D, Lacroix S. Astrocytes initiate inflammation in the injured mouse spinal cord by promoting the entry of neutrophils and inflammatory monocytes in an IL-1 receptor\/MyD88-dependent fashion. Brain Behav Immun. 2010;24:540\u201353.","journal-title":"Brain Behav Immun"},{"key":"2050_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.brainres.2008.07.035","volume":"1231","author":"S Liu","year":"2008","unstructured":"Liu S, Xu GY, Johnson KM, Echetebu C, Ye ZS, Hulsebosch CE, et al. Regulation of interleukin-1beta by the interleukin-1 receptor antagonist in the glutamate-injured spinal cord: endogenous neuroprotection. Brain Res. 2008;1231:63\u201374.","journal-title":"Brain Res"},{"key":"2050_CR28","doi-asserted-by":"crossref","unstructured":"Newell EA, Todd BP, Mahoney J, Pieper AA, Ferguson PJ, Bassuk AG. Combined blockade of interleukin-1alpha and -1beta signaling protects mice from cognitive dysfunction after traumatic brain injury. eNeuro. 2018;5.","DOI":"10.1523\/ENEURO.0385-17.2018"},{"key":"2050_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1460-9568.2011.07723.x","volume":"34","author":"F Clausen","year":"2011","unstructured":"Clausen F, Hanell A, Israelsson C, Hedin J, Ebendal T, Mir AK, et al. Neutralization of interleukin-1beta reduces cerebral edema and tissue loss and improves late cognitive outcome following traumatic brain injury in mice. Eur J Neurosci. 2011;34:110\u201323.","journal-title":"Eur J Neurosci"},{"key":"2050_CR30","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.bbi.2017.08.005","volume":"66","author":"M Sun","year":"2017","unstructured":"Sun M, Brady RD, Wright DK, Kim HA, Zhang SR, Sobey CG, et al. Treatment with an interleukin-1 receptor antagonist mitigates neuroinflammation and brain damage after polytrauma. Brain Behav Immun. 2017;66:359\u201371.","journal-title":"Brain Behav Immun"},{"key":"2050_CR31","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1038\/jcbfm.2012.101","volume":"32","author":"JM Pradillo","year":"2012","unstructured":"Pradillo JM, Denes A, Greenhalgh AD, Boutin H, Drake C, McColl BW, et al. Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. J Cereb Blood Flow Metab. 2012;32:1810\u20139.","journal-title":"J Cereb Blood Flow Metab"},{"key":"2050_CR32","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jvs.2008.04.011","volume":"48","author":"S Akuzawa","year":"2008","unstructured":"Akuzawa S, Kazui T, Shi E, Yamashita K, Bashar AH, Terada H. Interleukin-1 receptor antagonist attenuates the severity of spinal cord ischemic injury in rabbits. J Vasc Surg. 2008;48:694\u2013700.","journal-title":"J Vasc Surg"},{"key":"2050_CR33","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1080\/00207454.2018.1424154","volume":"128","author":"T Li","year":"2018","unstructured":"Li T, Li YT, Song DY. The expression of IL-1beta can deteriorate the prognosis of nervous system after spinal cord injury. Int J Neurosci. 2018;128:778\u201382.","journal-title":"Int J Neurosci"},{"key":"2050_CR34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.17712\/nsj.2015.2.20140483","volume":"20","author":"AE Hasturk","year":"2015","unstructured":"Hasturk AE, Yilmaz ER, Turkoglu E, Arikan M, Togral G, Hayirli N, et al. Potential neuroprotective effect of Anakinra in spinal cord injury in an in vivo experimental animal model. Neurosciences (Riyadh). 2015;20:124\u201330.","journal-title":"Neurosciences (Riyadh)"},{"key":"2050_CR35","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00401-018-1954-4","volume":"137","author":"A Otxoa-de-Amezaga","year":"2019","unstructured":"Otxoa-de-Amezaga A, Miro-Mur F, Pedragosa J, Gallizioli M, Justicia C, Gaja-Capdevila N, et al. Microglial cell loss after ischemic stroke favors brain neutrophil accumulation. Acta Neuropathol. 2019;137:321\u201341.","journal-title":"Acta Neuropathol"},{"key":"2050_CR36","doi-asserted-by":"crossref","unstructured":"Brennan FH, Jogia T, Gillespie ER, Blomster LV, Li XX, Nowlan B, et al. Complement receptor C3aR1 controls neutrophil mobilization following spinal cord injury through physiological antagonism of CXCR2. JCI Insight. 2019;4.","DOI":"10.1172\/jci.insight.98254"},{"key":"2050_CR37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/acn3.318","volume":"3","author":"FH Brennan","year":"2016","unstructured":"Brennan FH, Kurniawan ND, Vukovic J, Bartlett PF, Kasermann F, Arumugam TV, et al. IVIg attenuates complement and improves spinal cord injury outcomes in mice. Ann Clin Transl Neurol. 2016;3:495\u2013511.","journal-title":"Ann Clin Transl Neurol"},{"key":"2050_CR38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.neuroimage.2012.11.048","volume":"68","author":"M Harrison","year":"2013","unstructured":"Harrison M, O'Brien A, Adams L, Cowin G, Ruitenberg MJ, Sengul G, et al. Vertebral landmarks for the identification of spinal cord segments in the mouse. Neuroimage. 2013;68:22\u20139.","journal-title":"Neuroimage"},{"key":"2050_CR39","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.expneurol.2013.05.002","volume":"247","author":"LV Blomster","year":"2013","unstructured":"Blomster LV, Brennan FH, Lao HW, Harle DW, Harvey AR, Ruitenberg MJ. Mobilisation of the splenic monocyte reservoir and peripheral CX(3)CR1 deficiency adversely affects recovery from spinal cord injury. Exp Neurol. 2013;247:226\u201340.","journal-title":"Exp Neurol"},{"key":"2050_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/nbm.2829","volume":"26","author":"LV Blomster","year":"2013","unstructured":"Blomster LV, Cowin GJ, Kurniawan ND, Ruitenberg MJ. Detection of endogenous iron deposits in the injured mouse spinal cord through high-resolution ex vivo and in vivo MRI. NMR Biomed. 2013;26:141\u201350.","journal-title":"NMR Biomed"},{"key":"2050_CR41","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1089\/08977150360547099","volume":"20","author":"SW Scheff","year":"2003","unstructured":"Scheff SW, Rabchevsky AG, Fugaccia I, Main JA, Lumpp JE Jr. Experimental modeling of spinal cord injury: characterization of a force-defined injury device. J Neurotrauma. 2003;20:179\u201393.","journal-title":"J Neurotrauma"},{"key":"2050_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbi.2016.11.013","volume":"61","author":"JM Pradillo","year":"2017","unstructured":"Pradillo JM, Murray KN, Coutts GA, Moraga A, Oroz-Gonjar F, Boutin H, et al. Reparative effects of interleukin-1 receptor antagonist in young and aged\/co-morbid rodents after cerebral ischemia. Brain Behav Immun. 2017;61:117\u201326.","journal-title":"Brain Behav Immun"},{"key":"2050_CR43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.expneurol.2008.01.033","volume":"211","author":"D Gris","year":"2008","unstructured":"Gris D, Hamilton EF, Weaver LC. The systemic inflammatory response after spinal cord injury damages lungs and kidneys. Exp Neurol. 2008;211:259\u201370.","journal-title":"Exp Neurol"},{"key":"2050_CR44","doi-asserted-by":"publisher","first-page":"10715","DOI":"10.1523\/JNEUROSCI.0498-15.2015","volume":"35","author":"D Bastien","year":"2015","unstructured":"Bastien D, Bellver Landete V, Lessard M, Vallieres N, Champagne M, Takashima A, et al. IL-1alpha gene deletion protects oligodendrocytes after spinal cord injury through upregulation of the survival factor Tox3. J Neurosci. 2015;35:10715\u201330.","journal-title":"J Neurosci"},{"key":"2050_CR45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1742-2094-10-6","volume":"10","author":"F Boato","year":"2013","unstructured":"Boato F, Rosenberger K, Nelissen S, Geboes L, Peters EM, Nitsch R, et al. Absence of IL-1beta positively affects neurological outcome, lesion development and axonal plasticity after spinal cord injury. J Neuroinflammation. 2013;10:6.","journal-title":"J Neuroinflammation"},{"key":"2050_CR46","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1177\/0271678X15606714","volume":"36","author":"S Maysami","year":"2016","unstructured":"Maysami S, Wong R, Pradillo JM, Denes A, Dhungana H, Malm T, et al. A cross-laboratory preclinical study on the effectiveness of interleukin-1 receptor antagonist in stroke. J Cereb Blood Flow Metab. 2016;36:596\u2013605.","journal-title":"J Cereb Blood Flow Metab"},{"key":"2050_CR47","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12974-018-1058-z","volume":"15","author":"DD Zhang","year":"2018","unstructured":"Zhang DD, Jin C, Zhang YT, Gan XD, Zou MJ, Wang YY, et al. A novel IL-1RA-PEP fusion protein alleviates blood-brain barrier disruption after ischemia-reperfusion in male rats. J Neuroinflammation. 2018;15:16.","journal-title":"J Neuroinflammation"},{"key":"2050_CR48","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1136\/jnnp.2004.054882","volume":"76","author":"HC Emsley","year":"2005","unstructured":"Emsley HC, Smith CJ, Georgiou RF, Vail A, Hopkins SJ, Rothwell NJ, et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry. 2005;76:1366\u201372.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2050_CR49","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/jcbfm.2014.23","volume":"34","author":"A Helmy","year":"2014","unstructured":"Helmy A, Guilfoyle MR, Carpenter KL, Pickard JD, Menon DK, Hutchinson PJ. Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial. J Cereb Blood Flow Metab. 2014;34:845\u201351.","journal-title":"J Cereb Blood Flow Metab"},{"key":"2050_CR50","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1177\/0271678X15620204","volume":"36","author":"A Helmy","year":"2016","unstructured":"Helmy A, Guilfoyle MR, Carpenter KLH, Pickard JD, Menon DK, Hutchinson PJ. Recombinant human interleukin-1 receptor antagonist promotes M1 microglia biased cytokines and chemokines following human traumatic brain injury. J Cereb Blood Flow Metab. 2016;36:1434\u201348.","journal-title":"J Cereb Blood Flow Metab"},{"key":"2050_CR51","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1089\/089771501750451857","volume":"18","author":"O Nesic","year":"2001","unstructured":"Nesic O, Xu GY, McAdoo D, High KW, Hulsebosch C, Perez-Pol R. IL-1 receptor antagonist prevents apoptosis and caspase-3 activation after spinal cord injury. J Neurotrauma. 2001;18:947\u201356.","journal-title":"J Neurotrauma"},{"key":"2050_CR52","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1007\/s10753-011-9341-5","volume":"35","author":"S Zong","year":"2012","unstructured":"Zong S, Zeng G, Wei B, Xiong C, Zhao Y. Beneficial effect of interleukin-1 receptor antagonist protein on spinal cord injury recovery in the rat. Inflammation. 2012;35:520\u20136.","journal-title":"Inflammation"},{"key":"2050_CR53","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12974-014-0203-6","volume":"11","author":"BH Clausen","year":"2014","unstructured":"Clausen BH, Degn M, Martin NA, Couch Y, Karimi L, Ormhoj M, Mortensen ML, Gredal HB, Gardiner C, Sargent II, et al. Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia. J Neuroinflammation. 2014;11:203.","journal-title":"J Neuroinflammation"},{"key":"2050_CR54","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1523\/JNEUROSCI.5376-06.2007","volume":"27","author":"BW McColl","year":"2007","unstructured":"McColl BW, Rothwell NJ, Allan SM. Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J Neurosci. 2007;27:4403\u201312.","journal-title":"J Neurosci"},{"key":"2050_CR55","doi-asserted-by":"crossref","unstructured":"Fleming JC, Bailey CS, Hundt H, Gurr KR, Bailey SI, Cepinskas G, Lawendy AR, Badhwar A: Remote inflammatory response in liver is dependent on the segmental level of spinal cord injury. J Trauma Acute Care Surg 2012, 72:1194-1201;discussion 1202.","DOI":"10.1097\/TA.0b013e31824d68bd"},{"key":"2050_CR56","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.neuropharm.2008.06.074","volume":"55","author":"SJ Campbell","year":"2008","unstructured":"Campbell SJ, Zahid I, Losey P, Law S, Jiang Y, Bilgen M, et al. Liver Kupffer cells control the magnitude of the inflammatory response in the injured brain and spinal cord. Neuropharmacology. 2008;55:780\u20137.","journal-title":"Neuropharmacology"},{"key":"2050_CR57","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1089\/neu.2011.1860","volume":"28","author":"SM Lee","year":"2011","unstructured":"Lee SM, Rosen S, Weinstein P, van Rooijen N, Noble-Haeusslein LJ. Prevention of both neutrophil and monocyte recruitment promotes recovery after spinal cord injury. J Neurotrauma. 2011;28:1893\u2013907.","journal-title":"J Neurotrauma"},{"key":"2050_CR58","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/jcbfm.2010.103","volume":"31","author":"J Galea","year":"2011","unstructured":"Galea J, Ogungbenro K, Hulme S, Greenhalgh A, Aarons L, Scarth S, et al. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J Cereb Blood Flow Metab. 2011;31:439\u201347.","journal-title":"J Cereb Blood Flow Metab"},{"key":"2050_CR59","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1476-5381.2010.00684.x","volume":"160","author":"AD Greenhalgh","year":"2010","unstructured":"Greenhalgh AD, Galea J, Denes A, Tyrrell PJ, Rothwell NJ. Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection. Br J Pharmacol. 2010;160:153\u20139.","journal-title":"Br J Pharmacol"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-020-02050-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12974-020-02050-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-020-02050-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T18:28:57Z","timestamp":1609957737000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-020-02050-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2050"],"URL":"https:\/\/doi.org\/10.1186\/s12974-020-02050-6","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"30 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experiments were approved by The University of Queensland\u2019s Animal Ethics Committee (Anatomical Biosciences) and were conducted in accordance with the Australian Code for the Care and Use of Animals for Scientific Purposes.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}